Alice Pharma is officially listed on the Company's board today

On December 2nd, Alice Pharmaceuticals officially landed on the board.
Pharmaceuticals filed for an IPO in April this year, and is a biopharmaceutical industry company with a fifth set of listing standards, sponsored by CITIC Securities Co., Ltd.
According to the results of the Ailes Pharmaceuticals issue announcement, the company's share issue price of 22.73 yuan per share, a total size of about 2,045.7 million yuan, the funds raised will be mainly used for new drug research and development, headquarters and research and development base construction.
Screenshot Source: Reference: Mr. Du Jinhao, Chairman of Ales Pharmaceuticals, mentioned in a recent interview with the Pharmaceutical Mingkang content team that the successful listing of Ales Pharmaceuticals on the Tablet is an endorsement of the company's innovative capabilities by the capital market and an affirmation of Alice Pharmaceuticals' development strategy.
" next step, we will continue to enrich the product pipeline, develop high-efficiency and low-toxic products, so that patients do not suffer.
"he said, which is his responsibility and clear goal as head and founder of Alice Pharmaceuticals.
founded in 2004, Ailes Pharmaceuticals is an innovative pharmaceutical company focused on cancer treatment.
2019, Alice Pharma has completed two rounds of private equity financing, with valuations of 4 billion yuan and 4.8 billion yuan, respectively.
this time Alice Pharmaceuticals listed on the Board, strategic investors include Shanghai Pharmaceutical Group, Shanghai Pharmaceutical Holdings, Qingdao Baiyang Pharmaceuticals, Dasanlin Pharmaceuticals and so on.
According to the prospectus, Ales Pharmaceuticals Chairman Mr. Du Jinhao (Photo: Alice Pharmaceuticals) according to the prospectus, Ales Pharmaceuticals aims to develop the first-in-class and best-in-class drugs in the global pharmaceutical market, guided by unsuperenced clinical needs.
, it has built research and development pipelines in the field of small molecule-targeted drugs for non-small cell lung cancer (NSCLC), including 10 research projects in five major pharmaceutical research projects.
, the core product, methyl sulfonate vosantini, has been submitted for listing in China and has been included in the priority review.
, the third generation of EGFR-TKI is about to become commercial, Mr. Du Jinhao said in an interview, Alice Pharmaceuticals in the initial stage is from the development of innovative drugs.
16 years, the company has successfully developed two new Class 1 drugs.
, the first new drug, Alysatan esters, was successfully transferred in the early years.
second innovative drug, Vossinini, is also about to be approved for listing and commercialization.
is known to be the third representative of the skin growth factor subject tyrosine kinase inhibitor (EGFR-TKI).
EGFR is a group of cell surface bodies of epidermic growth factor families with tyrosine kinase activity, which activates several downstream signaling paths, including PI3K-Akt, MAPK-Erk, etc., to produce cell proliferation effects.
EGFR activation abnormality can activate genes associated with tumor proliferation and differentiation, which in turn induces tumor formation and development.
EGFR inhibitor action principle (screenshot source: Reference: Reference 1) EGFR inhibitors by competing with endogenetic ligation combined with EGFR, inhibit the activity of tyrosine kinase, block the EGFR signaling path, resulting in inhibition of tumor cell proliferation, metastasis and promote tumor cell apoptosis and a series of biological effects.
As a third-generation EGFR-TKI, Vomedini's uniqueness is reflected in four aspects: first, it has dual-active differentiation characteristics, and both the main active metabolite AST5902 and the prototype drug AST2818 can effectively inhibit EGFR-sensitive mutations and T790M resistance mutations; The effect on EGFR-sensitive mutations has almost no inhibitory effect on wild types, the third is safety, that is, there are few serious adverse reactions associated with drugs, in the registered clinical study of Vormetinib, the occurrence of adverse drug≥-related adverse reactions of class 3 drugs was 1.5%; Ms. Mu Yanping, CHIEF Executive Officer of
Ailes Pharmaceuticals (Photo Source: Alice Pharmaceuticals Website) According to the validity data submitted by Alice Pharmaceuticals to CDE in April this year, as of January 29, 2020, the objective remission rate (ORR) of the treatment of patients with local late stage or metastasis NSCLC who were positive for EGFR T790M mutation was 74.1%.
this means that vositeni is effective for 74.1% of patients (the effective criterion is 30% or more tumor reduction).
the study, the disease control rate (DCR) was 93.6%, the clinical benefit rate (CBR) was 79.5%, the medium progression-free lifetime (mPFS) was 9.6 months, and the medium remission duration (mDOR) was 8.3 months.
Based on this eye-catching data, Ales Pharmaceuticals submitted a conditional approval application for Vometinistinib to china's State Drug Administration (NMPA) in November 2019 for second-line treatment for non-small cell lung cancer.
noted that the product was also included in the CDE's priority review as an "innovative drug with clear therapeutic advantages".
Note: The adaptation is expected to be approved by the end of 2020, according to CDE's official website.
, Mr. Du said, the results were lucky for a 16-year-old innovative drug research and development company,
Innovator drug research and development can not be rushed to success, often not as fast as enough."
slow stew and the fire should be proper.
"In addition to second-line treatment for NSCLC, Phase 3 clinical trials of Vomedinib for EGFR-sensitive late-stage NSCLC first-line therapeutic adaptations were launched in June 2019 and are expected to be submitted for listing in 2022.
addition, Ales Pharmaceuticals will continue to expand the clinical application of vosodini, including combination therapy, postoperative ancillary therapy and so on.
in addition to the transition from lung cancer to new therapeutic areas through KRAS, Ales Pharmaceuticals has developed other innovative products around common drive gene targets in NSCLC, including RET inhibitors, KRAS G12C inhibitors, EGFR 20 exon insertion mutation inhibitors, and c-MET inhibitors.
these new drug programs are currently in the preclinical research phase.
, according to the prospectus, the company plans to submit a new drug clinical trial application (IND) for the research and development project between 2021 and 2023.
pharmaceutical in the study of products (photo source: References .
KRAS G12C inhibitors are mainly targeted at tumors caused by KRAS G12C mutations, including NSCLC, colorectal cancer, etc.
in the study of EGFR exon 20 insertion mutation inhibitors mainly for EGFR/HER2 exon 20 insertion mutation of late NSCLC.
in the study of c-MET inhibitors mainly for c-MET signal abnormalities of late NSCLC.
, according to Ms. Mu Yanping, the future of Alice Medicine from lung cancer to a new field of treatment, the best bridge in the process is kras as a target.
because KRAS is not just in lung cancer, it's also in some digestive tract tumors, which will help us move from lung cancer to other tumors."
," she said.
the signal pathway mediated by KraS (screenshot source: Reference: References) According to Ms. Mu Yanping, digestive tract tumors will become an important research and development area for the future of Ales Pharmaceuticals.
in China, digestive tract tumors are one of the high-risk tumor diseases, including stomach cancer up to 400,000 new cases a year, bowel cancer a year more than 200,000 new cases.
there are still huge unsealed clinical needs in this area.
review of the development of Alice Pharmaceuticals over the past 16 years, Mr. Du jinhao admitted that he had faced many difficulties.
he believes that only by discovering his own shortcomings will he have the possibility to strengthen and improve himself.
said the launch is a new starting point for Ales Pharmaceuticals, which will help the company better promote the development of more innovative products.
the future, the company will actively seek cooperation opportunities or introduce products based on independent research and development of innovative drugs, so as to build a wealth of product pipelines to bring more innovative therapies to patients.
References: The Ellis Pharmaceutical Prospectus. Retrieved Nov 25, 2020, from Alice's initial public offering of shares and announcement of the results of the listing of the Kotson board. Retrieved Nov 25, 2020, from the Drug Review Center of the State Drug Administration of China. Retrieved Nov 25, 2020, from #: Medical Mission Hills follow medicinal.com WeChat Public No